Wuttke H, Schlieter D
Med Klin. 1980 Aug 29;75(18):658-62.
In 81 patients the thyrotoxicosis was controlled with antithyroid drugs only. Ophthalmopathy was seen in 53 patients when therapy was started. Patients with ophthalmopathy stage V or VI were excluded from this study. Maximal pathological eye signs were seen in 24 patients before starting therapy. Worsening occurred during treatment in 16 patients and some months after therapy was stopped in 13 patients. In summary, 40 patients passed a phase of subnormal thyroid hormone levels. Although stimulated, thyrotrophin secretion during this phase of antithyroid drug treatment took place in 19 patients a time related, reversible progression of endocrine ophthalmopathy was seen only in one subject. During medical treatment of a relapse in this patient worsening of eye signs had been seen once more despite thyrotrophin secretion was suppressed. The results are discussed in view of an immunologic concept of the pathogenesis of Graves' disease.
81例患者仅用抗甲状腺药物控制甲状腺毒症。开始治疗时,53例患者出现眼病。V期或VI期眼病患者被排除在本研究之外。24例患者在开始治疗前出现最大程度的病理性眼部体征。16例患者在治疗期间病情恶化,13例患者在停药数月后病情恶化。总之,40例患者经历了甲状腺激素水平低于正常的阶段。尽管受到刺激,但在抗甲状腺药物治疗的这个阶段,19例患者出现促甲状腺素分泌,仅1例患者出现与时间相关的、可逆的内分泌性眼病进展。在该患者复发的药物治疗期间,尽管促甲状腺素分泌受到抑制,但眼部体征再次恶化。鉴于Graves病发病机制的免疫学概念对结果进行了讨论。